Results 221 to 230 of about 85,817,771 (286)

Interleukin-6 regulates the neutrophil response to diverse bacteria. [PDF]

Front Immunol
Owens JM, Weppner HK, Ignes-Romeu A, Burleson JW, Hind LE.   +4 more
europepmc   +1 more source

Interleukin‐39 is a Prognostic Biomarker and Therapy Target for Sepsis

Advanced Science, EarlyView.
Sepsis triggers a significant increase in IL‐39 production, with circulating levels markedly elevated and positively correlated with disease severity and poor clinical prognosis in sepsis patients. Mechanistically, macrophage‐derived IL‐39 activates the GP130 signaling pathway via a ligand‐receptor interaction, thereby fueling the pro‐inflammatory ...
Feng‐zhi Zhang, Hai‐jun Liu, Yan Yue, Jun‐jie Gao, Jin Zhang, Wen‐wu Zhang, Yun‐long Zhang, Wei‐hua Lu, Sheng‐wei Jin, Pu‐hong Zhang   +9 more
wiley   +1 more source

Contribution of Interleukin-6 (IL-6) to Body Defense and Healing in Pulmonary Tuberculosis. [PDF]

Saudi Med J
Junaidi H, Adi AC, Soedarsono, Soetjipto, Wahyuni CU, Syahrul F, M Kes M, S Km Z, Arfan I, Mamun AA, Sari R.   +10 more
europepmc   +1 more source

Collagen‐Binding IL‐15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self‐Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity

Advanced Science, EarlyView.
Repurposing the dense tumor stroma from a physical barrier into an anchoring scaffold, an engineered oncolytic adenovirus encoding IL15C‐CBD overcomes the immunosuppressive microenvironment in triple‐negative breast cancer. Intratumoral viral replication secretes this collagen‐anchored immunocytokine, forming a localized cytokine depot.
Yaqi Yang, Xiaoxiao Liu, Junqiang Ding, Jinliang Xu, Jianhua Zhang, Hanchang Zhang, Rong Yang, Sha Li, Lu Zheng, Runping Su, Yue Zhao, Jianxiao Wu, Hao Li, Changyou Zhan, Xihui Gao   +14 more
wiley   +1 more source

Interleukin-6 levels decrease following rituximab treatment but increase following tocilizumab treatment. [PDF]

Ann Hematol
Ide M, Fukumoto T, Ohnishi H, Okamura S, Kawano K, Yokoyama T, Kameda T.   +6 more
europepmc   +1 more source

Spatiotemporally Controlled Sequential Chemo‐Immunotherapy Activates Pyroptosis for Robust Anti‐Tumor Immunotherapy

Advanced Science, EarlyView.
A glutathione and ultrasound dual‐responsive cerasome achieves sequential co‐delivery of gemcitabine and BMS1166 in tumors. Chemotherapy priming followed by on‐demand PD‐L1 blockade synergistically amplifies anti‐tumor immunity, inhibiting primary tumor growth, distant metastasis and inducing durable immune memory.
Suhui Sun, Ruiqi Wu, Qingshuang Tang, Yunli Xu, Wanrui Shi, Mengxin Wang, Haonan Wang, Yan Luo, Cheng Ma, Xiaolong Liang   +9 more
wiley   +1 more source

The role of interleukin-6 in diabetic retinal disease: pathophysiology and therapeutic targeting. [PDF]

Front Immunol
Harlow REA, Rose-John S, Haskova Z, Fauser S, Mesquida M.   +4 more
europepmc   +1 more source

TP53 Loss Elevates NF‐κB‐IFN‐β‐MHC‐Ia Signaling to Promote NK Cell Resistance in Osteosarcoma

Advanced Science, EarlyView.
TP53 loss in a transforming or osteosarcoma cell promotes cytosolic DNA accumulation, activating NF‐κB‐dependent IFN‐β production. Autocrine IFN‐β signaling increases cell‐surface HLA‐Ia expression, strengthens inhibitory KIR signaling in natural killer cells, and thereby enables the affected cell to evade NK cell‐mediated cytotoxicity.
Guihui Qin, Cheung Kwan Yeung, Ye Yi, Dejin Zheng, Miaoman Ye, Chi‐Chong Chio, Jinjie Wu, Siyi Fu, Chu‐Xia Deng, Ren‐He Xu   +9 more
wiley   +1 more source

Type I interferon limits interleukin-6 signalling in SLE through shedding interleukin-6 receptors. [PDF]

Rheumatology (Oxford)
Hempel M, Klapproth E, Krause A, Becker-Pauly C, Zeissig S, Heschel B, Weser N, Fantana J, Leuchten N, Rose-John S, El-Armouche A, Korb-Pap A, Aringer M.   +12 more
europepmc   +1 more source